For example, pre-clinical studies investigating the administration of IL-10 or IL-10 receptor agonists have shown promising results in inflammatory bowel disease (IBD) [151], where excessive pro-inflammatory cytokines play a significant role in disease pathogenesis. The gene discussed is IL10; the disease is inflammatory bowel disease.